One of the big challenges with cancer research is sorting out the wheat from the chaff in terms of viable targets.

If you think about it, just as we have drivers and passengers in traditional targeted therapy approaches to consider, there are also valid targets versus markers in immuno-oncology too.

We have written quite a bit about novel targeted therapy approaches of late and now it’s time to switch to IO again.

Sometimes aiming at a particular target might lead to a series of rather disappointing results in certain tumour types, yet suddenly looks much more intriguing and useful in a quite different setting.

We’ve talked about finding the sweet spot in aiming at the right cell, right compartment quite a bit on BSB, and this latest example certainly fits into this category…

To learn more from our oncology analysis and get a heads up on the latest insights and analysis pertaining to oncology R&D, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by